SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
of Report (Date of earliest event reported): December 11, 2019
Name if Business Issuer as specified in its Charter)
|(State or other Jurisdiction
233 Needham Street,
Newton MA, 02464
|(Address of principal
executive offices, including zip code)|
telephone number including area code)|
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
pursuant to Rule 1 4a- 12 under the Exchange Act (17 CFR 240.1 4a- 12)|
communications pursuant to Rule 1 4d-2(b) under the Exchange Act (17 CFR 240.1 4d-2(b))|
communications pursuant to Rule 1 3e-4(c) under the Exchange Act (17 CFR 240.1 3e-4(c))|
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company ☐
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
registered pursuant to Section 12(b) of the Act:
of each class
of each exchange on which registered|
December 11, 2019, Bioxytran issued a new investor presentation is available on its website at www.bioxytraninc.com.
9.01. Financial Statements and Exhibits.
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dr. David Platt|
||Dr. David Platt|
||President and Chief Executive Officer|
||Dated: December 11, 2019|